Stockreport

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen  FDA agreed to proposed changes to the EMBRAVE3 [Read more]